Clinical trial Recruiting at 1 site Interventional Ages 18 and up

Clareon PanOptix versus AcrySof PanOptix for contrast vision after cataract surgery

Official title: Clareon PanOptix Versus AcrySof PanOptix : Prospective Study Comparing Contrast Sensitivity. Study of Two Different Material of Intra Ocular Multifocal Lenses Aiming to Compare the Effect on Contrast Sensitivity.

Run by Assistance Publique - Hôpitaux de Paris · NCT07158177 · Data updated 2026-11-12

This study will try Clareon PanOptix in one eye and AcrySof PanOptix in the other to see which lens gives better contrast vision three months after cataract surgery for adults seeking presbyopia correction.

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment40 (estimated)
SponsorAssistance Publique - Hôpitaux de Paris
Academic / other
Locations1 site (Paris, Île-de-France Region)
StatusRecruiting
StartedOctober 1, 2025
Main results expectedOctober 15, 2026
Study endsOctober 15, 2026
Registry record updatedMarch 30, 2026
Trial IDNCT07158177 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults (≥18) presenting for cataract surgery who want presbyopia-correcting trifocal IOLs, have comparable cataract density in both eyes, and have no significant ocular comorbidities are ideal candidates.

Probably not a fit

Patients with retinal disease, glaucoma, prior significant anterior or posterior segment pathology, active intraocular inflammation, pregnancy, or those unsuitable for multifocal IOLs are unlikely to benefit from this comparison.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

In a randomized, contralateral design, each participant receives one Clareon PanOptix IOL in one eye and one AcrySof PanOptix IOL in the other during routine cataract surgery. Follow-up visits occur at day 3–10 and 1 month with standard care, and the primary 3-month visit includes contrast sensitivity testing and non-invasive aberrometry (I-Trace). Both toric and non-toric trifocal lenses are allowed, and patients are managed at a single center in Paris. The protocol focuses on contrast vision differences between the two CE-marked IOLs in otherwise healthy eyes eligible for multifocal implantation.

Why it matters

Potential benefit: If successful, the results could help surgeons choose the IOL that provides better contrast vision and overall visual quality for patients wanting presbyopia correction.

How similar studies have gone: Previous comparisons of trifocal and multifocal IOLs have shown similar acuity outcomes with mixed or modest differences in contrast sensitivity, so this contralateral randomized comparison builds on existing but not definitive evidence.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Patients ≥ 18 years of age
* Patients presenting for cataract surgery in routine clinical practice and eligible for multifocal IOL implantation (toric and non-toric)
* Patients with grade 2/3 cataract density and comparable visual acuity in both eyes
* Patient with a pregnancy test (negative pregnancy test), if applicable
* Patient with signed consent to participate in the study
* Patient affiliated to a social security scheme or entitled beneficiary

Exclusion Criteria:

* Children \< 18 years of age
* Pregnancy or breast-feeding in progress or planned during the study.
* History of anterior (cornea, anterior chamber, sulcus) or posterior (uveal, vitreoretinal) segment pathology, including retinal vascular occlusive disease, retinal detachment or peripheral retinal laser photocoagulation, AMD, glaucoma.
* Any inflammation of the anterior or posterior segment, whatever the etiology, and/or history of any disease with intraocular inflammatory repercussions.
* Clinically significant corneal pathology (epithelial, stromal and/or endothelial) that could have an impact on visual results.
* Clinically significant moderate or severe dry eye that could affect study measurements.
* History of intraocular or corneal surgery (refractive or trauma-related).
* Presence or history of amblyopia or monofixation syndrome.
* Subjects with conditions that increase the risk of zonular disruption during the phacoemulsification procedure that may affect the centration or postoperative orientation of the IOL.
* Any other planned eye surgery, including, but not limited to, limbal relaxing incision (LRI)/astigmatic keratotomy and laser refractive surgery (LASIK).
* Irregular astigmatism identified by corneal topography
* Patients under guardianship, curatorship or safeguard of justice, as well as pregnant or breast-feeding women (article L1121-5 of the CSP).1.1
* Patient under AME

Where it's running

  • Assistance Publique - Hôpitaux de Paris, Ophtalomopôle - Hôpital COCHIN
    Paris, Île-de-France Region, France
    Recruiting

Study contacts

  • Principal investigator: Dominique MONNET, MD, PhD — Université Paris Cité, Faculté de Santé / UFR de médecine
  • Study coordinator: Dominique MONNET, MD, PhD
  • Email: dominique.monnet@aphp.fr
  • Phone: 01 58 41 22 01

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.